PTC Therapeutics, Inc.

When Zevra Therapeutics, then known as KemPharm, bought arimoclomol for peanuts with its acquisition of Orphazyme in 2022, it looked like a great bit of business and further confirmation has come wi

The European Medicines Agency was this week deciding whether the planned EU marketing authorization applications (MAAs) for three investigational products deserved accelerated assessments – apitegroma

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp